(function(){var loadHandler=window['sl_{D0ADD9BC-5BCE-4B01-85F9-188A7AEC90E6}'];loadHandler&&loadHandler(179, '<div id="spr0_aefa147"><div id="spr1_aefa147" class="kern slide"><img id="img1_aefa147" src="data/img2.png" width="720px" height="540px" alt="" style="left:0px;top:0px;"/></div><div id="spr2_aefa147" class="kern slide"><div id="spr3_aefa147" style="left:64.125px;top:156.699px;"><img id="img0_aefa147" src="data/img262.png" width="591.75" height="366" alt=""/></div><div id="spr4_aefa147"><div style="width:0px;"><span id="txt0_aefa147" data-width="422.789063" style="left:35.179px;top:0.058px;">Combining endocrine treatment with</span></div><div style="width:0px;"><span id="txt1_aefa147" data-width="248.458984" style="left:122.869px;top:33.658px;">other targeted agents</span></div></div><div id="spr5_aefa147" style="left:253.046px;top:518.189px;"><div style="width:0px;"><span id="txt2_aefa147" class="relpos" data-width="62.455078" style="left:7.2px;top:2.082px;">Turner et al. </span><span id="txt3_aefa147" class="relpos" data-width="24.328125" style="left:7.195px;top:2.082px;">2015</span><span id="txt4_aefa147" class="relpos" style="left:7.19px;top:2.082px;"> </span><span id="txt5_aefa147" class="relpos" data-width="108.257813" style="left:7.185px;top:2.082px;">N Engl J Med. 373:209</span></div></div><div id="spr6_aefa147" style="top:90.88px;"><div style="width:0px;"><span id="txt6_aefa147" data-width="419.214844" style="left:151.61px;top:0.564px;">Fulvestrant + Palbociclib (CDK4/6 inhibitor)</span></div><div style="width:0px;"><span id="txt7_aefa147" data-width="194.619141" style="left:262.91px;top:29.87px;">Advanced breast cancer</span></div></div></div></div>');})();